Clinical trials: Locally Advanced Urothelial Carcinoma
Locally Advanced or Metastatic Urothelial Carcinoma
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally…
- Trial name
- NCT04568304
- Testing
- Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection
- Where
- 3 sites in China
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Urothelial Carcinoma
A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma
This study will evaluate the efficacy and safety of RC48-ADC combined with AK104 in HER2-expression locally advanced or metastatic urothelial carcinoma.
- Trial name
- NCT06178601
- Testing
- RC48-ADC, AK104
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Shanxi Province Cancer Hospital
Cancer
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
This was a multi-center, open-label, Phase 1, first-in-human (FIH), dose-escalation, and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of SRK-181…
- Trial name
- NCT04291079
- Testing
- SRK-181, anti-PD-(L)1 antibody therapy
- Where
- 22 sites in United States, South Korea
- Volunteers
- 112 people
- Sponsor
- Scholar Rock, Inc.
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Non-small Cell Lung Cancer, Gastric Cancer
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010
The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or…
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT05867121
- Testing
- RO7496353, Atezolizumab, Capecitabine
- Where
- 27 sites in United States, Australia and 7 more
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
- Trial name
- FORAGER-2 (NCT07218380)
- Testing
- Vepugratinib, EV, Pembrolizumab
- Where
- 276 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- Eli Lilly and Company
Bladder Neoplasms, Ureteral Neoplasms
TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium
Phase 2B, multicenter study evaluating the safety and efficacy of weekly TOCOSOL Paclitaxel in taxane-naive patients receiving second line chemotherapy for metastatic or locally advanced, unresectable transitional cell carcinoma…
- Conditions
- Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Carcinoma, Transitional Cell
- Trial name
- NCT00077688
- Testing
- TOCOSOL Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- Achieve Life Sciences
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Muscle Invasive Bladder Cancer, Urothelial Carcinoma
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
The objective is to investigate the efficacy and safety of four cycles of ddMVAC with G-CSF support in patients with MIBC and locally advanced UC
- Conditions
- Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Neoadjuvant Chemotherapy
- Trial name
- NCT04047693
- Testing
- dose dense MVAC with pegylated GCSF
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Pusan National University Yangsan Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00005958
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Sponsor
- Amgen
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
This research study is an open label study designed to evaluate the safety and translational correlative changes of the combination of propranolol hydrochloride and immune checkpoint inhibitors (ICI) in subjects with urothelial…
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- NCT04848519
- Testing
- Pembrolizumab, Propranolol Hydrochloride, Nivolumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Urothelial Carcinoma
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mocetinostat is an orally administered histone deacetylase (HDAC) inhibitor. This study is a Phase 2 trial evaluating the efficacy of mocetinostat in patients that have advanced urothelial carcinoma that has specific changes in…
- Trial name
- NCT02236195
- Testing
- Mocetinostat
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Cancers, Solid Tumor Cancer
A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or…
- Conditions
- Solid Cancers, Solid Tumor Cancer, Solid Tumor Malignancy, Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
- Trial name
- NCT06630247
- Testing
- XL495, ADC cytotoxic agents
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Exelixis
Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
This is a Phase 1b/2 multi-center, open-label study to establish the initial safety and to determine a recommended Phase 2 dose of B-701 in combination with pembrolizumab, and to determine safety, tolerability and efficacy of…
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases
- Trial name
- FIERCE-22 (NCT03123055)
- Testing
- B-701, Pembrolizumab
- Where
- 52 sites in United States, Belgium and 15 more
- Volunteers
- 28 people
- Sponsor
- Rainier Therapeutics
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors…
- Conditions
- Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT07020117
- Testing
- [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aktis Oncology, Inc.
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes…
- Conditions
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT04878029
- Testing
- Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
- Trial name
- NCT04879329
- Testing
- disitamab vedotin, pembrolizumab
- Where
- 221 sites in United States, Argentina and 10 more
- Volunteers
- 372 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Bladder Cancer Stage IV
Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Study of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy
- Trial name
- NCT04562311
- Testing
- Chidamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University